Five-Year Retention of Perampanel and Polytherapy Patterns: 328 Patients From a Single Center in South Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Perampanel (PER) is an α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid antagonist used to treat focal and generalized epilepsy. Comprehensive data from real-world settings with long-term follow-ups are still scarce. This study aimed to determine the factors related to PER retention and the polytherapy pattern with PER. Methods We reviewed all patients with epilepsy with a history of PER prescription during 2008–2017 and over a follow-up of >3 years. PER usage patterns and associated factors were analyzed. Results Among the 2,655 patients in the cohort, 328 (150 females, 178 males) were enrolled. The ages at onset and diagnosis were 21.1±14.7 years and 25.6±16.1 years (mean±standard deviation), respectively. The age at the first visit to our center was 31.8±13.8 years. Seizure types were focal, generalized, and unknown onset in 83.8%, 15.9%, and 0.3% of patients, respectively. The most common etiology was structural (n=109, 33.2%). The maintenance duration of PER was 22.6±19.2 months (range=1–66 months). The initial number of concomitant antiseizure medications was 2.4±1.4 (range=0–9). The most common regimen was PER plus levetiracetam (n=41, 12.5%). The median number of 1-year seizures before PER usage was 8 (range=0–1,400). A seizure reduction of >50% was recorded in 34.7% of patients (52.0% and 29.2% in generalized and focal seizures, respectively). The 1-, 2-, 3-, 4-, and 5-year retention rates for PER were 65.3%, 50.4%, 40.4%, 35.3%, and 21.5%, respectively. A multivariate analysis indicated that lower age at onset was associated with longer retention (p=0.01). Conclusions PER was safely used in patients with diverse characteristics and was maintained for a long time in a real-world setting, especially in patients with a lower age at onset.
Abstract
Background and Purpose Perampanel (PER) is an α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid antagonist used to treat focal and generalized epilepsy. Comprehensive data from real-world settings with long-term follow-ups are still scarce. This study aimed to determine the factors related to PER retention and the polytherapy pattern with PER. Methods We reviewed all patients with epilepsy with a history of PER prescription during 2008–2017 and over a follow-up of >3 years. PER usage patterns and associated factors were analyzed. Results Among the 2,655 patients in the cohort, 328 (150 females, 178 males) were enrolled. The ages at onset and diagnosis were 21.1±14.7 years and 25.6±16.1 years (mean±standard deviation), respectively. The age at the first visit to our center was 31.8±13.8 years. Seizure types were focal, generalized, and unknown onset in 83.8%, 15.9%, and 0.3% of patients, respectively. The most common etiology was structural (n=109, 33.2%). The maintenance duration of PER was 22.6±19.2 months (range=1–66 months). The initial number of concomitant antiseizure medications was 2.4±1.4 (range=0–9). The most common regimen was PER plus levetiracetam (n=41, 12.5%). The median number of 1-year seizures before PER usage was 8 (range=0–1,400). A seizure reduction of >50% was recorded in 34.7% of patients (52.0% and 29.2% in generalized and focal seizures, respectively). The 1-, 2-, 3-, 4-, and 5-year retention rates for PER were 65.3%, 50.4%, 40.4%, 35.3%, and 21.5%, respectively. A multivariate analysis indicated that lower age at onset was associated with longer retention (p=0.01). Conclusions PER was safely used in patients with diverse characteristics and was maintained for a long time in a real-world setting, especially in patients with a lower age at onset.
참고문헌 (29)
- GBD 2017 US Neurological Disorders Collaborators, "Burden of neurological disorders across the US from 1990-2017 : a global burden of disease study", JAMA Neurol, 78, pp.165~176 (2021)
- Kanner AM, "Antiseizure medications for adults with epilepsy : a review", JAMA, 327, pp.1269~1281 (2022)
- Kwan P, "Early identification of refractory epilepsy", N Engl J Med, 342, pp.314~319 (2000)
- French JA, "Adjunctive perampanel for refractory partial-onset seizures : randomized phase III study 304", Neurology, 79, pp.589~596 (2012)
- French JA, "Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures : results of randomized global phase III study 305", Epilepsia, 54, pp.117~125 (2013)
- Krauss GL, "Randomized phase III study 306 : adjunctive perampanel for refractory partial-onset seizures", Neurology, 78, pp.1408~1415 (2012)
- French JA, "Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial", Neurology, 85, pp.950~957 (2015)
- Steinhoff BJ, "A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria", Epilepsy Res, 108, pp.986~988 (2014)
- Rohracher A, "Two-year real-world experience with perampanel in patients with refractory focal epilepsy : Austrian data", Ther Adv Neurol Disord, 9, pp.445~453 (2016)
- Villanueva V, "Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting : the FYDATA study", Epilepsy Res, 126, pp.201~210 (2016)
- Chiang HI, "Preliminary Asian experience of using perampanel in clinical practice", Biomed J, 40, pp.347~354 (2017)
- Lin KL, "Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy : the first real-world evaluation in Asian pediatric neurology clinics", Epilepsy Behav, 85, pp.188~194 (2018)
- Morano A, "Perampanel as adjunctive therapy in highly refractory epilepsies : real-world data from an Italian tertiary care epilepsy centre", J Neurol Sci, 390, pp.67~74 (2018)
- Rohracher A, "Perampanel in routine clinical use across Europe : pooled, multicenter, observational data", Epilepsia, 59, pp.1727~1739 (2018)
- Villanueva V, "Perampanel in routine clinical use in idiopathic generalized epilepsy : the 12-month GENERAL study", Epilepsia, 59, pp.1740~1752 (2018)
- Chang RS, "Efficacy and tolerability of perampanel as an adjunct therapy in refractory epilepsy from real-world experience", J Neurol Sci, 405, pp.116416~ (2019)
- Abril Jaramillo J, "Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice : Spain prospective study(PERADON)", Epilepsy Behav, 102, pp.106655~ (2020)
- Lattanzi S, "Adjunctive perampanel in older patients with epilepsy : a multicenter study of clinical practice", Drugs Aging, 38, pp.603~610 (2021)
- Sagar P, "Efficacy and tolerability of adjuvant perampanel : an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes", Epilepsy Behav, 119, pp.107935~ (2021)
- Inoue Y, "Evaluation of real-world effectiveness of perampanel in Japanese adults and older adults with epilepsy", Epileptic Disord, 24, pp.123~132 (2022)
- Villanueva V, "PERMIT study : a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice", J Neurol, 269, pp.1957~1977 (2022)
- Wechsler RT, "PROVE : retrospective, non-interventional, phase IV study of perampanel in real-world clinical care of patients with epilepsy", Epilepsia Open, 7, pp.293~305 (2022)
- 황수경, "Real-Life Effectiveness and Tolerability of Perampanel in Pediatric Patients Aged 4 Years or Older with Epilepsy: A Korean National Multicenter Study", Journal of Clinical Neurology, 16(1), pp.53~59 (2020), 대한신경과학회
- Scheffer IE, "ILAE classification of the epilepsies : position paper of the ILAE commission for classification and terminology", Epilepsia, 58, pp.512~521 (2017)
- Toledano Delgado R, "Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures : experience from a national multicenter registry", Epilepsia, 61, pp.1109~1119 (2020)
- Yamamoto T, "Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission : the open-label Study 342(FREEDOM Study)", Epilepsia Open, 5, pp.274~284 (2020)
- Nishida T, "Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures : a comparative study of Asian and non-Asian populations", Epilepsia, 60(Suppl 1), pp.47~59 (2019)
- Potschka H, "Perampanel: does it have broad-spectrum potential?", Epilepsia, 60(Suppl 1), pp.22~36 (2019)
- Segal E, "Perampanel in real-world clinical care of adolescent and adult patients with epilepsy : results from the retrospective phase IV PROVE study", Seizure, 98, pp.87~94 (2022)